Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Molecular Partners (SIX/NASDAQ: MOLN) reported clinical progress for MP0317 in the randomized Phase 2 TACTIC trial in first-line advanced biliary tract carcinoma (cholangiocarcinoma). The investigator-initiated French study plans to enroll 75 patients (2:1 randomization; 50 experimental, 25 control) comparing MP0317 plus standard-of-care durvalumab and gemcitabine-cisplatin chemotherapy versus standard-of-care alone.
Nine expert sites are activated and patients are being treated. A data update is expected in 2027, with study completion targeted for 2028. A trial-in-progress poster has been accepted for the ESMO Congress 2026. MP0317, a FAP-localized CD40 agonist, previously showed tumor-localized CD40 activation and tumor microenvironment remodeling in a completed 46-patient Phase 1 study, whose results were published in Nature Cancer in 2026.
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) is presenting new data on its bispecific and multispecific Radio-DARPins at the Gordon Research Conference on Radionuclide Theranostics for the Management of Cancer in Newry, Maine, on July 15, 2026. The talk, given by SVP Targeted Radio Therapeutics Daniel Steiner, focuses on designing DARPins that align binding properties, half-life, and biodistribution with tumor and disease biology to overcome target limitations in radioligand therapy.
The company highlights mono-targeting and multispecific formats, including bispecific constructs and 2-in-1 DuoDARPins, intended to address tumor heterogeneity and co-expressed tumor targets. Lead candidate MP0712 (DLL3; with Orano Med) is in a US Phase 1/2a trial, while MP0726 (MSLN) is progressing toward first human imaging and a third Radio-DARPin program is planned for 2026.
Molecular Partners (NASDAQ:MOLN) reported pipeline progress for its targeted alpha Radio-DARPin therapeutics. The Phase 1/2a US trial of MP0712, a 212Pb-based DLL3-targeted candidate for small cell lung and neuroendocrine cancers, is dosing patients, with initial data expected in the coming months and broader efficacy readout in 2027.
Compassionate use work with 225Ac/177Lu DLL3 Radio-DARPin MP0714 has started in South Africa. Second candidate MP0726 targeting MSLN is planned for first-in-human imaging in H2 2026. The company also plans two IND filings in 2027 and a new RDT target nomination in H2 2026.
Molecular Partners (SIX:MOLN; NASDAQ:MOLN) and Orano Med announced that first patients have been dosed in a US multicenter Phase 1/2a trial of DLL3-targeting, 212Pb-labelled Radio-DARPin MP0712.
The study uses a matched-pair imaging/therapy design, is recruiting at five US sites, and plans up to four dose levels. Initial data are expected in the coming months, with comprehensive safety and efficacy readout in 2027.
Molecular Partners (NASDAQ:MOLN) will present trial-in-progress posters on its DLL3-targeting radio-DARPin MP0712 at ASCO 2026 in Chicago and SNMMI 2026 in Los Angeles.
The ongoing US Phase 1/2a trial is dosing the first cohort, with initial clinical data expected in 2026.
Molecular Partners (NASDAQ:MOLN), a clinical-stage biotech focused on DARPin therapeutics, will participate in TD Cowen’s 7th Annual Oncology Innovation Summit on May 27, 2026, at 11:30am ET.
The fireside chat will be webcast and accessible via the company’s website under the investors tab.
Molecular Partners (SIX: MOLN, NASDAQ: MOLN) reported Q1 2026 highlights, including initiation of clinical studies for MP0712 and MP0317 and progress across its DARPin pipeline.
The company held CHF 79 million in cash and short-term deposits as of March 31, 2026, with runway into late 2027.
Molecular Partners (NASDAQ: MOLN) will present oral talks on its lead Radio-DARPin candidate MP0712, a 212Pb-based DLL3-targeting therapeutic for small cell lung cancer, at three scientific meetings in May 2026: NCI SCLC Consortium (May 7), PEGS Boston (May 13) and Antibody & Engineering Therapeutics Basel (May 29).
Molecular Partners (NASDAQ: MOLN) published Phase 1 data in Nature Cancer for MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation. The Phase 1 dose‑escalation (46 patients) showed biomarker proof‑of‑mechanism, tumor microenvironment remodeling, a favorable safety profile up to the highest dose, and PK suitable for weekly or every‑3‑week dosing. An investigator‑initiated randomized Phase 2 in front‑line cholangiocarcinoma (N=75, 2:1 randomization, eight sites activated) is open with dosing ongoing.
Molecular Partners (NASDAQ: MOLN) will present three AACR 2026 posters with preclinical and early clinical data for novel DARPin candidates. MP0632 is a logic-gated Switch-DARPin T cell engager showing tumor regression in MSLN/EpCAM co-expressing models with limited activity on single-antigen tumors, suggesting a favorable therapeutic window. MP0712 is a 212Pb Radio-DARPin with high DLL3 affinity, half-life extension and promising biodistribution plus first patient imaging data; MP0712 is in a US Phase 1/2a trial for SCLC.
Presentations occur 4/20/2026 and 4/22/2026; posters to be posted after AACR.